New artificial intelligence technology is helping diagnose the U.S.’s most deadly cancer sooner, greatly improving the ...
Amtagvi monotherapy achieved a 25.6% objective response rate and 71.8% disease control rate in NSCLC patients without ...
Results from a phase 1/2 clinical trial (NCT05099172) show the safety and efficacy of sevabertinib (BAY2927088) in patients with non–small cell lung cancer (NSCLC) harboring HER2 or EGFR mutations. 1 ...
October brought several updates in the lung cancer field, ranging from notable trial results to patient-centered perspectives ...
About 40% of people with non-small cell lung cancer (NSCLC)—a type of cancer that begins in the tissues of your lungs—have metastatic disease at the time of their diagnosis. Metastatic NSCLC refers to ...
FDA grants accelerated approval to Bayer's Hyrnuo and full approval to Amgen's Imdelltra, expanding treatment options for ...
Ask a clinical question and tap into Healio AI's knowledge base. Lung cancer is generally the top cause of cancer-related death globally and in the United States (US). In the US in 2023, lung cancer ...
The nod brings Bayer face-to-face in the market with Boehringer Ingelheim and AstraZeneca, each of which has its own HER2 ...
A new randomized trial from North Carolina suggests that digital tools like mPATH may slightly boost participation in CT lung ...
SurvivorNet on MSN
Defying the Odds With Small Cell Lung Cancer: Montessa Lee’s 19-Year Journey Is a Beacon of Hope
Diagnosed with small-cell lung cancer at 28, Montessa Lee has defied the odds for nearly 20 years, surviving a disease with a ...
Future SCLC treatment may involve combining T-cell engagers with immune checkpoint inhibitors to enhance patient outcomes.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback